Business & Industry

Danaher Prepares to Introduce Advanced AI-Powered Laboratory

Yuvraj — Thu, 08 Oct 2026 13:36:21 +0000

In a significant step for pharmaceutical research, Danaher has announced plans to launch its first AI-powered autonomous research facility. Expected to become fully operational in early 2027 at the Abcam headquarters in Cambridge, UK, the upcoming AI autonomous lab will combine robotics, artificial intelligence, and proprietary technologies into a single, unified workflow. This closed-loop system […]

The post Danaher Prepares to Introduce Advanced AI-Powered Laboratory first appeared on World Pharma Today.

$1.8 Billion Commitment to Centralize Biological Data

Yuvraj — Thu, 08 Oct 2026 13:28:21 +0000

The United States government, alongside technology enterprises Meta Platforms and Alphabet, is officially joining forces with the nonprofit organization Biohub. This collaborative effort aims to construct comprehensive open datasets designed to train advanced AI models for biological research, elevating the total investment in this initiative to $1.8 billion. Financial Contributions and Strategic Partnerships In a […]

The post $1.8 Billion Commitment to Centralize Biological Data first appeared on World Pharma Today.

India’s ₹2,333 Crore Weight-Loss Drug Story: Mounjaro, Semaglutide and the Next Phase of Competition

Yuvraj — Mon, 05 Oct 2026 11:45:55 +0000

India’s weight-loss drug story has moved well beyond a niche pharmaceutical category. GLP-1 medicines are now creating a rapidly expanding business around obesity and metabolic health, with Mounjaro and semaglutide at the centre of the competition. India’s GLP-1 segment reached ₹2,333 crore in sales for the 12 months ended August 2026. Unit sales grew 74% […]

The post India’s ₹2,333 Crore Weight-Loss Drug Story: Mounjaro, Semaglutide and the Next Phase of Competition first appeared on World Pharma Today.

Hengrui Pharma and Novo Nordisk Sign Licensing Deal for Oral GLP-1/GIP Dual Agonist HRS-1596

Yuvraj — Wed, 30 Sep 2026 12:53:05 +0000

Hengrui Pharma has entered into a licensing agreement with Novo Nordisk for HRS-1596, a phase I-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist with potential for once-weekly oral dosing, in a deal valued at up to 2.6 billion US dollars. Agreement Structure and Financial Terms Under the terms of the […]

The post Hengrui Pharma and Novo Nordisk Sign Licensing Deal for Oral GLP-1/GIP Dual Agonist HRS-1596 first appeared on World Pharma Today.

US Details Eligibility for Section 232 Specialty Pharmaceutical Tariff Exemptions

Yuvraj — Wed, 30 Sep 2026 12:37:44 +0000

The Trump administration has released detailed guidance regarding specialty pharmaceutical tariff exemptions for products including orphan treatments, nuclear medicines, cell and gene therapies, and antibody-drug conjugates (ADCs). Effective September 29, 2026, these rules allow specific drug classes to enter the United States duty-free, bypassing broad 100% Section 232 tariffs on patented pharmaceutical products and ingredients. […]

The post US Details Eligibility for Section 232 Specialty Pharmaceutical Tariff Exemptions first appeared on World Pharma Today.

Roche and Earendil Forge $1.5 Billion Bispecific Antibody Discovery Deal

Yuvraj — Sat, 26 Sep 2026 04:50:59 +0000

Roche-owned Genentech has entered into a major collaboration with Earendil Labs to discover and develop bispecific antibodies targeting oncology, in a deal valued at up to $1.5 billion. Deal Structure and Financial Terms Under the terms of the agreement, Earendil will receive $55 million upfront, along with up to $1.445 billion in development, regulatory, and […]

The post Roche and Earendil Forge $1.5 Billion Bispecific Antibody Discovery Deal first appeared on World Pharma Today.

AbbVie and Iambic Partner to Accelerate AI Drug Discovery in Immunology, Neuroscience and Oncology

Yuvraj — Fri, 25 Sep 2026 13:37:17 +0000

AbbVie and Iambic have entered into a multiyear collaboration focused on AI drug discovery across three major therapeutic areas — immunology, neuroscience, and oncology. The partnership brings together Iambic’s molecular superintelligence platform and AbbVie’s established drug discovery expertise, with the shared goal of identifying and developing small molecule therapies with first-in-class and best-in-class potential. Financial […]

The post AbbVie and Iambic Partner to Accelerate AI Drug Discovery in Immunology, Neuroscience and Oncology first appeared on World Pharma Today.

Treatment for Rare Disease cALD Approved by European Commission

Yuvraj — Fri, 25 Sep 2026 13:18:35 +0000

Neuraxpharm and Minoryx Therapeutics have secured European Commission approval for Nezglyal (leriglitazone), making it the first approved drug therapy for rare disease cALD — cerebral adrenoleukodystrophy — in the European Union, with a commercial launch expected before the end of the year. The regulatory green light marks a significant milestone in the treatment landscape for […]

The post Treatment for Rare Disease cALD Approved by European Commission first appeared on World Pharma Today.

FDA Advisory Panel Votes in Favour of GRAIL Galleri Multi-Cancer Early Detection Test

Yuvraj — Thu, 24 Sep 2026 11:18:53 +0000

A United States Food and Drug Administration advisory panel has voted in favour of approving GRAIL’s Galleri, positioning the multi-cancer early detection test for a potential landmark regulatory decision in the months ahead. Panel Votes Across Three Key Dimensions The ten voting members of the FDA’s Molecular and Clinical Genetics Devices advisory panel evaluated the […]

The post FDA Advisory Panel Votes in Favour of GRAIL Galleri Multi-Cancer Early Detection Test first appeared on World Pharma Today.

InnoCare Pharma Signs $3.35 Billion Strategic Licensing Agreement with Eli Lilly

Yuvraj — Thu, 24 Sep 2026 11:05:52 +0000

Chinese biopharmaceutical company InnoCare Pharma has entered into a strategic research collaboration and licensing agreement with Eli Lilly and Company to develop new medicines, with total potential payments reaching approximately $3.35 billion. Agreement Structure and Financial Terms Under the terms of the agreement, InnoCare will leverage its proprietary drug discovery platform and internal research capabilities […]

The post InnoCare Pharma Signs $3.35 Billion Strategic Licensing Agreement with Eli Lilly first appeared on World Pharma Today.